Draxxin (Tulathromycin) Injectable Solution, Antibiotic 100mg (50 mL)
Licensed U.S. Pharmacy | Licensed Pharmacy

Draxxin (Tulathromycin) Injectable Solution, Antibiotic 100mg (50 mL)

Item# MWI30209
FREE SHIPPING Over $49! * Pet Food & Other Exclusions
1. Select strength:
2. Select size:
QTY:-+
$409.99$532.99
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
$171.99Reg $223.99
$429.99Reg $558.99
$409.99Reg $532.99
$759.99Reg $985.99
$1,806.99Reg $2,348.99
$3,439.99Reg $4,471.99

Related Items

  • Description
  • Directions
  • Reviews

Description

Draxxin Injectable Solution is an antibiotic indicated for the treatment of bovine respiratory disease (BRD), infectious bovine keratoconjunctivitis (IBK) and foot rot in beef and non-lactating dairy cattle and for treatment and control of swine respiratory disease (SRD) in swine.

    BRD - Draxxin Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. IBK - Draxxin Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.

    Foot Rot - Draxxin Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.

    SRD - Draxxin Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

Prescription Required

Directions

Cattle Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site.

Table 1. DRAXXIN Cattle Dosing Guide
Animal Weight (Pounds) Dose Volume (mL)
100 1.1
200 2.3
300 3.4
400 4.5
500 5.7
600 6.8
700 8.0
800 9.1
900 10.2
1000 1.4

Swine Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

Table 2. DRAXXIN Swine Dosing Guide
Animal Weight (Pounds) Dose Volume (mL)
15 0.2
30 0.3
50 0.6
70 0.8
90 1.0
110 1.3
130 1.5
150 1.7
170 1.9
190 2.2
210 2.4
230 2.6
250 2.8
270 3.1
290 3.3

CONTRAINDICATIONS: The use of DRAXXIN Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

NOT FOR USE IN CHICKENS OR TURKEYS

    RESIDUE WARNINGS

    Cattle: Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. Do not use in female dairy cattle 20 months of age or older.

    Swine: Swine intended for human consumption must not be slaughtered within 5 days from the last treatment

    PRECAUTIONS:

    CATTLE: The effects of DRAXXIN on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

    SWINE: The effects of DRAXXIN on porcine reproductive performance, pregnancy, and lactation have not been determined. Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

    ADVERSE REACTIONS

    Cattle: In one BRD field study, two calves treated with DRAXXIN at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia.

    Swine: In one field study, one out of 40 pigs treated with DRAXXIN at 2.5 mg/kg BW exhibited mild salivation that resolved in less than four hours.